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Abbreviations 
ALA: alpha linoleic acid 
ALT: alanine transaminase 
AST: aspartate transaminase 
BMI: body mass index 
CRP:  C-reactive protein 
CV: coefficients of variation 
CVD: cardio vascular disease 
GGT: gamma-glutamyl transpeptidase 
T2DM: type 2 diabetes mellitus 
WC: waist circumference 
WHpR: waist:hip ratio 
WHtR: waist:height ratio  
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Abstract 
Dysregulation of adipose hormones in obesity has been associated with the hastened development of 
metabolic syndrome and associated chronic disease sequalae including cardiovascular disease and 
type 2 diabetes mellitus. This study aims to identify common biochemical and anthropometric 
markers that impact adipose hormones, including adiponectin and leptin. Based on previous literature, 
it was hypothesized that these would be adversely impacted by liver function parameters and 
adiponectin levels would be positively correlated with phospholipid omega-3 fatty acids. Forty non-
diabetic adult subjects (body mass index (BMI)≥25.0kg/m²) were recruited. Fasting plasma samples 
were taken to assess adipokine levels, glucose metabolism, electrolytes, liver enzymes, and blood 
lipids. Basic anthropometric measurements were also recorded. Adiponectin levels were positively 
correlated with HDL cholesterol and negatively correlated with anthropometric measures, insulin, 
liver enzymes, triglycerides, and VLDL cholesterol but not BMI. Conversely, plasma leptin levels 
were positively correlated with anthropometric measures, C-reactive protein, HDL cholesterol, and 
plasma phospholipid proportions of omega-3 alpha linoleic acid, but inversely correlated with 
creatinine levels. These results support other data regarding correlations between adiponectin and 
relative adipose distribution. Correlations with specific liver enzymes may indicate that adiponectin 
levels are tied to fatty acid deposition in the liver; however, liver/kidney damage though further 
mechanistic clarification is required. Leptin levels were associated with measures of adiposity but not 
liver enzymes. Each of these variables, along with blood lipids, may serve as potential future 
therapeutic targets for the prevention and management of obesity and related co-morbidities. 
Keywords: human, obesity, adipokines, liver enzymes, cholesterol, fatty acids. 
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1. Introduction 
Overweight and obesity have been identified as major public health problems worldwide [1], resulting 
in increased mortality and relative risk of disease [2].
 
Estimates from 2008 suggest that 1.4 billion 
adults worldwide were overweight and of these, approximately 500 million were obese [3]; with 
approximately 2.8 million adults dying annually as a result of overweight and obesity [4].  
Dieting, weight loss, and exercise constitute a multi-billion dollar industry [5], but unfortunately,  
most dieters inevitably regain weight as current methods to maintain weight loss have poor long-term 
success rates [6, 7]. There remains a limited understanding of the physiological processes regulating 
appetite control and energy expenditure, which has fundamentally hindered development of truly 
effective therapies to treat or prevent obesity [8]. Adipocytes produce a number of biologically active 
proteins that assist in the regulation of energy intake and expenditure; these are also referred to as 
adipokines. These adipose hormones, including adiponectin [9] and leptin [10, 11], have been 
identified as potential therapeutic targets in the prevention and treatment of obesity.  
Low plasma adiponectin concentrations (hypoadiponectinemia) are linked to T2DM (male and female 
subjects, mean BMI 23.8kg/m
2
) [12] and hypertension (male subjects, mean BMI 23.9kg/m
2
) [13]. 
Low adiponectin levels were also independently associated with all causes of mortality, cardiac 
mortality, and myocardial infarction in male subjects presenting with chest pain [9]. This hormone has 
many regulatory actions on energy homeostasis, glucose balance, and fatty acid metabolism, and it 
enhances glucose metabolism in the liver and skeletal muscle [14-17].  
Circulating levels of leptin change relative to food intake and adiposity [18, 19]. In non-obese 
subjects, leptin acts to inhibit feeding and increase thermogenesis [20]. In obesity, where weight is 
stable, higher plasma leptin levels do not induce the expected reduction in food intake and increase in 
energy expenditure, suggesting the development of resistance to the effects of endogenous leptin [21-
23]. Where energy intake is restricted in obese subjects, administration of low doses of leptin is able 
to prevent decrease appetite and improve energy expenditure [24], factors that would otherwise hinder  
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weight loss [25]. To this extent, it appears that responsiveness to leptin in obesity is retained relative 
to a significant change in leptin levels and not to sustained circulating levels under basal conditions. 
Significant alterations in circulating levels of adiponectin and leptin, and their physiological roles in 
the pathogenesis of obesity lead to the hypothesis that they may be involved in the progression 
towards metabolic syndrome, vascular disease, and T2DM. This study aims to identify additional 
anthropometric and biochemical markers correlated with circulating measures of adiponectin and 
leptin in obese subjects, with particular consideration given to the identification of potential 
therapeutic targets. Liver enzymes [26] and fatty acid indices [27] are recognized as components of 
metabolic syndrome and have led authors to further investigate potential correlations between these 
parameters and adipokine levels. Based on the current biochemical understanding of these hormones, 
it was hypothesized that adiponectin would be inversely correlated with liver function parameters and 
positively correlated with phospholipid omega-3 fatty acids. Conversely, it was hypothesized that 
leptin levels would be positively correlated with liver function parameters. With a focus on 
identifying parameters that may indicate increased risk of obesity and the progression towards 
metabolic syndrome within the general population, consideration was given to both male and female 
participants from a broad age range. 
2. Methods and Materials 
2.1 Participants 
A total of forty subjects were recruited from within the greater Brisbane region. Even numbers of 
male and female participants were recruited, with 10 overweight and 30 obese subjects in total. All 
subjects were over the age of 18 with a BMI≥25.0kg/m2. Participants were non-diabetic, non-smokers, 
who were not pregnant/breastfeeding, reported no active substance abuse (alcohol or drug 
dependency), and were generally healthy. Subjects were not currently taking cholesterol medications 
or nutritional supplements.  Written informed consent was obtained from all subjects.  
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2.2 Study Design 
Anthropometric measures included height, weight, waist circumference (WC), and hip circumference. 
WC was measured to the nearest 0.1 cm at the umbilicus level. Hip circumference was measured to 
the nearest 0.1 cm at the widest point between the iliac crest and buttock. BMI was calculated as 
weight in kilograms divided by the square of the height in meters (kg/m
2
). BMI groups were based on 
World Health Organization classifications for adults [28]. Overweight BMI range was categorized as 
25.0kg/m
2 ≤BMI>30.0kg/m2 and a BMI≥30.0kg/m2 was classified as obese.  
Fasting blood samples were taken, for the quantification of adipokine levels (total adiponectin and 
leptin), markers of glucose metabolism, electrolyte and liver function, cholesterol, and plasma fatty 
acid phospholipids. The study design was approved by Metro South Human Research Ethics 
Committee (HREC/10/QPAH/141) and The University of Queensland Medical Research Ethics 
Committee (2010001200). 
2.3 Assays 
Total adiponectin was measured in duplicate by Cardinal Bioresearch (Brisbane), utilizing Multiplex 
ELISA techniques on a Luminex platform with human adiponectin/Acrp30 [29] and following the 
standard procedures outlined in the corresponding Human Obesity MultiAnalyte Profiling Base Kit 
[30]. These assays demonstrated a mean minimum detectible dose of 6.4pg/mL and a CV of 9.2-
14.6% for inter-assay variation and 2.8-5.6% for intra-assay variation. Total leptin was measured in 
duplicate using human leptin antibodies [31] supplied by R&D Systems and following the standard 
procedures outlined in the corresponding Human MultiAnalyte Profiling Base Kit B [32]. These 
assays demonstrated a mean minimum detectible dose of 7.69pg/mL and a CV of 7.2-11.2% for inter-
assay variation and 4.6-8.0% for intra-assay variation. Plasma phospholipid concentrations were 
measured by gas chromatography based on one sample each, and in conjunction with FOODplus 
Institute at The University of Adelaide, Waite Campus [33]. Free fatty acids were measured in 
duplicate using a nonesterified free fatty acid  assay from Wako Diagnostics in Osaka, Japan [34]. All 
other pathological markers were analyzed by Pathology Queensland (Princess Alexandra Hospital, 
Brisbane). 
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2.4 Statistical Analyses 
All data are expressed as means ± standard deviation. Relationships between variables were assessed 
by nonparametric correlation analysis (Spearman’s rank correlation coefficient). The sample size of 
40 was determined to allow correlations between variables of 0.37 or more to be detected with a 
power of 0.80 at a level of significance of P=0.05. P values <0.05 were considered of statistical 
significance. All statistical analyses were performed in SPSS version 20.0. 
3. Results 
Anthropometric measures, adipokine levels, and metabolic parameters are summarized in Table 1. 
Subjects were between 23 and 79 years of age with a BMI between 26.4kg/m
2
 to 46.9kg/m
2 
(mean 
value 32.8kg/m
2
). Indirect measures of adipose distribution including WC, waist:height ratio (WHtR), 
and waist:hip ratio (WHpR) were all higher in obese than overweight cohorts. There were no 
significant differences in adiponectin levels between overweight and obese participants (7.7 vs 
7.1ug/mL; P=0.52). Leptin levels did not differ significantly between overweight and obese 
participants (23.2 vs 33.0ng/mL; P=0.14). The mean insulin level for all subjects was 7.9mU/L, mean 
total cholesterol was 5.mmol/L, and there were no significant differences between overweight and 
obese groups. 
Table 2 shows Spearman’s correlation coefficients (r) and coefficients of variation (CV) for 
adiponectin levels. Significant correlations between adiponectin and key anthropometric measures 
included WC (r=-0.61, P<0.01), WHtR (r=-0.39, P=0.01), and WHpR (r=-0.47, P<0.01). Of these, 
WC demonstrated the highest correlation with a CV of 37%. There was no significant correlation 
observed between adiponectin and BMI (r=-0.26, P=0.10). Insulin was inversely correlated with 
adiponectin levels (r=-0.49, P=0.01), as were alanine transaminase (ALT; r=-0.54, P<0.01), aspartate 
transaminase (AST; r=-0.44, P<0.01), gamma-glutamyl transpeptidase (GGT; r=-0.60, P<0.01), and 
urate (r=-0.55, P<0.01).  In contrast, urea:creatinine was positively correlated with adiponectin levels 
(r=0.48, P<0.01). Significant inverse correlations were also observed between adiponectin and blood 
lipids, including triglycerides (r=-0.47, P<0.01), HDL:Total (r=-0.42, P=0.01), and VLDL (r=-0.44, 
P<0.01) but not total cholesterol. Conversely, HDL cholesterol levels were positively correlated with 
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adiponectin (r=0.52, P<0.01). Circulating adiponectin levels were also inversely correlated with 
plasma phospholipid percentages of saturated fatty acids (r=-0.66, P<0.01) and positively correlated 
with trans-saturated fatty acids (r=0.34, P=0.03). No direct correlation was observed between 
adiponectin levels and phospholipid percentages of omega-3 or omega-6 fatty acids. 
Table 3 shows Spearman’s correlation coefficients and CV for leptin levels. ositive correlations with 
anthropometric measures included BMI (r=0.44, P<0.01) and WHtR (r=0.34, P=0.03) but not WC or 
WHpR. Of these, BMI demonstrated the highest correlation with a CV of 18%. There were no 
significant correlations between markers of glucose metabolism and leptin levels, though creatinine 
(r=-0.51, P<0.01) and C-reactive protein (CRP; r=0.47, P=0.01) from the liver function and 
electrolytes panel were highly correlated. Leptin levels were positively correlated with HDL 
cholesterol (r=0.40, P=0.01) and inversely correlated with the HDL:Total ratio (r=-0.55, P<0.01). Of 
the plasma phospholipids, ALA was positively correlated with plasma leptin levels (r=0.33, P=0.04). 
No significant correlations were observed between levels of free fatty acids and adiponectin (r=0.03, 
P=0.88) or leptin (r=0.11, P=0.51). 
Of further interest, insulin levels were positively correlated with anthropometric measures including 
WC (r=0.61, P<0.01) and WHtR (r=0.48, P≤0.01). Insulin was also inversely correlated with urea 
(r=-0.46, P=0.01) and positively correlated with estimated glomerular filtration rate (r=0.56, P=0.02), 
gamma-glutamyl transpeptidase (r=0.49, P<0.01), and ALT (r=0.44, P=0.02). 
4. Discussion 
Adiponectin and leptin are key regulators of energy homeostasis and may be key determinants of the 
progression and development of obesity [9-11]. This manuscript aims to identify anthropometric and 
biochemical markers that correlate with each of these hormones in overweight and obese subjects. 
This includes particular consideration of parameters that may serve as potential therapeutic targets in 
the future.  
In relation to anthropometric parameters, the strongest association for adiponectin was WC. This 
inverse correlation has previously been observed by Shober et al. [35] in a combined cohort of 
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diabetic and non-diabetic adults (mean BMI 29.8kg/m
2
, overweight). Contrary to previous data [36], 
no significant correlation to BMI was observed within this overweight/obese cohort. Inverse 
correlations were observed between adiponectin and WHtR as well as WHpR. This supports reports 
from other studies suggesting the relative distribution of body mass (as represented in this study by 
WC, WHtR, and WHpR) [37, 38] and not simply increased relative adiposity (approximated using 
BMI). Conversely, leptin levels were positively correlated with BMI and WHtR but not WC or 
WHpR. Previous studies have also observed correlations between leptin and both total and central fat 
mass [10, 11, 39]. Given the correlations between levels of these hormones and CVD risk [9], these 
data support previous thoughts regarding the role of BMI as a proxy for quantifying obesity risk as 
well as the significance of more recent indices of abdominal obesity, including WC, WHtR, and 
WHpR [40]. 
The relationship between obesity, insulin resistance and T2DM is not yet clearly understood, in 
particular the correlation with adipose tissues and adipokines. This study found that the strongest 
correlation for adiponectin relating to glycaemic control was insulin (inverse), whilst no significant 
associations were identified with leptin in this area. Previous data have also identified positive 
correlations between adiponectin, glycaemic control [36], and insulin sensitivity [41], as well as 
inverse associations with  HbA1c [9] and insulin resistance [37, 38]. Cortisol [42] and insulin [42, 43] 
have also been correlated with leptin expression and secretion. The absence of these indications may 
be suggestive of changes in leptin sensitivity within an overweight/obese cohort. 
Elevations in liver enzymes are common in obese subjects and have been associated with increased 
fatty acid deposition in the liver [44, 45]. Leptin, but not adiponectin, was significantly inversely 
correlated with creatinine, a metabolic by-product of skeletal muscle metabolism that is observed to 
be lower in subjects with lower muscle mass [46]. Significant inverse correlations were observed 
between plasma adiponectin levels and liver enzymes such as ALT, AST GGT. This is of particular 
interest given previous correlations between ALT and AST with liver injury, alcoholic cirrhosis, and 
liver congestion and non-alcoholic fatty liver disease [47-50].  
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Insulin levels were also negatively correlated with plasma adiponectin levels, although positively 
associated with ALT and GGT. Through correlations with fatty acid deposition in the liver, ALT and 
GGT have been identified as important biomarkers for the development of metabolic syndrome  [51, 
52] and elevated cardiovascular risk [51]. As adiponectin levels are also inversely correlated with 
obesity [53], these results indicate that adiponectin may provide a common denominator between 
elevations in liver enzymes and hyperinsulinemia in obesity and the subsequent development of 
metabolic syndrome. 
In combination with negative correlations with triglycerides, positive correlations were observed 
between adiponectin and HDL cholesterol. These results concur with previous data [36, 41, 54] and 
are consistent with the role of adiponectin in the up regulation of lipid uptake and oxidation in skeletal 
muscle, inhibiting hepatic triglyceride synthesis. No significant correlations were observed between 
adiponectin and total or LDL cholesterol levels [27]. 
Similarly, leptin has been shown to increase hepatic fatty acid oxidation and plasma triglyceride as 
well as reduce triglyceride secretion into plasma [55, 56]. However, this study found minimal 
correlations between leptin and lipid profiles. No significant correlations were found between leptin 
and triglycerides or total cholesterol. This contrasted with previous data from Kalhan et al. [57] who 
reported significant correlations between plasma leptin and both of these levels in South American 
males of Asian descent (age 24.2±1.9 years). The discrepancy between these results may be 
attributable to differences in the mean BMI of these studies (22.0±2.9kg/m² vs 32.8±4.8kg/m²), with 
increased adipose tissue linked to abnormal lipid profiles (hyperlipidaemia) [58]. However, the 
present study did observe significant positive correlations between leptin and HDL cholesterol, with 
concurrent inverse correlations to HDL:total cholesterol ratios. Of further note is the absence of 
observed correlations between plasma leptin levels and free fatty acids. Given the association between 
leptin and changes in energy intake and expenditure, this contrasts with widely accepted literature 
which proposes that increased free fatty acid concentrations associated with obesity play a role in the 
subsequent adverse metabolic effects [59]. In contrast, more recent data suggests that the 
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concentration of free fatty acids per kilogram of adipose tissue decreases as total adiposity increases,  
in many cases leading to the normalization of free fatty acid levels in obese subjects [60].  
In regards to cholesterol analyses, adiponectin levels were significantly correlated with plasma 
phospholipid percentages of trans-saturated fatty acids and inversely correlated to saturated fatty acid 
levels. Despite existing data indicating increased adiponectin levels associated with omega-3 
supplementation [61, 62], no significant correlations were observed to plasma phospholipid levels of 
omega-3 or omega-6. Conversely, leptin was significantly positively associated with plasma 
phospholipid levels of alpha linoleic acid. Previous studies have shown reductions in leptin associated 
with conjugated linoleic acid supplementation in rats [63] and marine lipid (eicosapentaenoic acid and 
docosahexaenoic acid) consumption in humans [64].  
By contrast, this study found a significant inverse correlation between adiponectin levels and the 
percentage of saturated fatty acids as well as a positive correlation with plasma phospholipid trans-
saturated fatty acids. Leptin was also found to be positively correlated with the plasma phospholipid 
percentage of omega-3 ALA. Neither adiponectin nor leptin were significantly correlated with plasma 
phospholipid total omega-3, eicosapentaenoic acid, and docosahexaenoic acid percentages. This 
contrasts with data from other human studies reporting increased levels of adiponectin and leptin 
associated with omega-3 fatty acid intake (eicosapentaenoic acid/docosahexaenoic acid from marine 
lipid origin) in overweight/obese subjects [61, 65]. Clearly, these findings will need to be replicated in 
further studies in order to determine plausible reasons for this apparent contrast in results. 
Results support correlations between adiponectin and relative adipose distribution, whilst leptin levels 
were associated with measures of both adipose distribution and relative adiposity (BMI). With 
correlations between these hormones and CVD [9], these results lend further credence and potential 
mechanistic understanding to the importance of both BMI and measures of abdominal obesity in 
quantifying the relative health risk of individuals. 
Significant correlations between adiponectin and levels of hepatic enzymes (ALT and AST) are 
concurrent with previous literature indicating the role of adiponectin in hepatic fatty acid metabolism 
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[14-17]. Elevations in these enzymes have been associated with non-alcoholic fatty liver disease. 
These correlations may provide some indication of the role of adiponectin in the development of this 
condition.  
Limitations are naturally inherent within the design and outcomes of any study. Although the sample 
size of this study was sufficient in meeting the desired aims, future trials incorporating a larger cohort 
would allow for additional subanalyses for variables such as age, gender, and menopausal status. 
Results are limited to overweight and obese subjects, so further studies would be needed for 
comparison to normal weight participants. The correlations between adipokines and 
anthropometric/biochemical parameters do not necessarily indicate the existence of a causal 
relationship or associated mechanisms. Thus, further intervention studies are necessary to investigate 
the extent of the clinical implications associated with these findings.  
Accordingly, these results are found to partially support the hypothesis since adiponectin levels were 
observed to be inversely correlated with liver function parameters but not correlated with plasma 
phospholipid fatty acids. In contrast to the original hypothesis, leptin levels demonstrated minimal 
correlations to liver enzymes, although they were positively correlated with phospholipid omega-3 
ALA. 
These markers, along with blood lipids that were also correlated with these hormones (HDL 
cholesterol, triglycerides, saturated fatty acids, trans saturated fatty acids, and omega-3 alpha linoleic 
acid) may serve as potential future therapeutic targets for the prevention and management of obesity 
and related co-morbidities. 
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Table 1: Baseline anthropometric and metabolic parameters for overweight and obese subjects 
Metabolic Parameters 
Overweight  Obese  
Male Female Male Female 
Anthropometric Parameters         
Age (years) 42.97 ±10.97 48.62 ±6.86 40.86 ±9.96 46.41 ±13.15 
BMI (kg/m
2
) 28.18 ±0.51 27.81 ±1.21 33.44 ±3.66 35.27 ±4.96 
WC (m) 1.00 ±0.10 0.89 ±0.08 1.15 ±0.09 1.03 ±0.16 
WHtR 0.55 ±0.04 0.54 ±0.06 0.64 ±0.04 0.63 ±0.09 
WHpR 0.93 ±0.09 0.79 ±0.07 0.99 ±0.06 0.85 ±0.11 
Adipokines 
Adiponectin (ug/mL) 5.83 ±0.84 9.56 ±1.47 5.69 ±2.93 8.37 ±3.94 
Leptin (ng/mL) 9.46 ±4.02 36.92 ±6.77 19.31 ±10.28 46.57 ±22.87 
Insulin Sensitivity 
Glucose (mmol/L) 5.80 ±1.26 5.12 ±0.29 5.09 ±0.30 5.22 ±0.62 
Insulin (mU/L) 7.70 ±5.37 5.60 ±1.35 9.25 ±5.00 7.20 ±3.79 
HbA1C (NgSP; %) 5.48 ±0.25 5.24 ±0.05 5.53 ±0.39 5.60 ±0.55 
HbA1C (IFCC; mmol/mol) 36.60 ±2.87 33.40 ±0.49 37.00 ±4.23 37.80 ±5.97 
Electrolyte and Liver Function 
ALT (U/L) 23.80 ±5.91 20.80 ±6.58 43.20 ±27.55 27.80 ±19.01 
AST (U/L) 18.80 ±5.38 16.40 ±2.80 26.67 ±9.43 22.73 ±10.34 
GGT (U/L) 14.80 ±3.06 16.20 ±6.05 26.00 ±10.54 16.80 ±7.30 
Urea (mmol/L) 5.46 ±1.91 5.76 ±1.14 5.44 ±1.09 4.73 ±0.93 
Creatinine (mmol/L) 84.00 ±13.34 60.40 ±6.53 82.87 ±7.49 63.67 ±13.28 
Urea:Creatinine  65.00 ±19.30 94.60 ±14.26 65.33 ±11.19 75.40 ±12.49 
Urate (mmol/L) 0.39 ±0.06 0.27 ±0.07 0.42 ±0.08 0.30 ±0.05 
CRP (mh/L) 1.13 ±0.05 2.05 ±0.84 4.18 ±3.56 6.50 ±4.48 
Blood Lipids 
Total Cholesterol (mmol/L) 5.02 ±0.77 5.46 ±0.98 5.34 ±0.96 5.32 ±1.21 
Triglycerides (mmol/L) 1.06 ±0.23 0.63 ±0.30 1.69 ±0.93 1.03 ±0.44 
HDL (mmol/L) 1.04 ±0.16 1.70 ±0.42 1.02 ±0.16 1.31 ±0.27 
HDL:Total  4.94 ±0.59 3.30 ±0.39 5.30 ±1.09 4.10 ±0.86 
LDL(mmol/L) 3.52 ±0.65 3.44 ±0.52 3.54 ±0.70 3.52 ±1.08 
VLDL (mmol/L) 0.48 ±0.12 0.28 ±0.15 0.77 ±0.43 0.47 ±0.21 
Free Fatty Acids (mEq/L) 0.20 ±0.09 0.27 ±0.19 0.31 ±0.15 0.37 ±0.12 
Plasma Phospholipid Levels (%) 
Saturated Fatty Acids 45.03 ±0.64 44.37 ±0.21 45.18 ±0.46 44.53 ±0.89 
Transaturated Fatty Acids 0.56 ±0.14 0.55 ±0.11 0.55 ±0.15 0.60 ±0.13 
Omega-3 Fatty Acids (total) 6.08 ±1.84 5.79 ±0.67 6.09 ±1.29 5.99 ±0.81 
Alpha linoleic acid 0.15 ±0.05 0.22 ±0.08 0.16 ±0.04 0.23 ±0.09 
Eicosapentaenoic acid  0.92 ±0.37 1.03 ±0.11 1.28 ±0.81 0.98 ±0.37 
Docosahexaenoic acid 3.88 ±1.28 3.41 ±0.72 3.39 ±0.53 3.56 ±0.50 
Omega-6 Fatty Acids (total) 35.48 ±3.30 35.23 ±1.92 34.40 ±1.95 34.61 ±1.28 
Omega-3:Omega-6 0.18 ±0.06 0.17 ±0.03 0.18 ±0.05 0.17 ±0.03 
10 overweight (5 male, 5 female; 25.0 kg/m
2 ≤ BMI>30.0 kg/m2) and 30 obese (15 male, 15 female; 
BMI≥30.0kg/m2) participants were included in the study. Due to insufficient plasma sample for some 
participants, one or more analytes may have been omitted. Data represents means ± SD. BMI, Body Mass 
Index; WC, waist circumference; WHtR, Waist:Height Ratio; WHpR, Waist:Hip Ratio; ALT, alanine 
transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transpeptidase; CRP, C-reactive 
protein.  
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Table 2. Spearman’s correlation coefficients and CVs for adiponectin levels 
Metabolic Parameters n 
Spearman’s correlation CV 
(r
2
 x 100) r P Value 
Anthropometric Parameters     
BMI (kg/m
2
) 40 -0.26 0.10 7% 
WC (m) 40 -0.61 <0.01 37% 
WHtR 40 -0.39 0.01 15% 
WHpR 40 
-0.47 <0.01 22% 
Insulin Sensitivity 
Glucose (mmol/L) 40 -0.15 0.35 2% 
Insulin (mU/L) 40 -0.49 0.01 24% 
HbA1C (NgSP; %) 40 -0.20 0.21 4% 
HbA1C (IFCC; mmol/mol) 40 
-0.20 0.21 4% 
Electrolyte and Liver Function 
ALT (U/L) 40 -0.54 <0.01 29% 
AST (U/L) 40 -0.44 <0.01 19% 
GGT (U/L) 40 -0.60 <0.01 36% 
Urea (mmol/L) 40 0.25 0.12 6% 
Creatinine (mmol/L) 40 -0.25 0.12 6% 
Urea:Creatinine  40 0.48 <0.01 23% 
Urate (mmol/L) 40 -0.55 <0.01 30% 
CRP (mh/L) 40 -0.32 0.07 10% 
Blood Lipids 
Total Cholesterol (mmol/L) 40 0.13 0.42 2% 
Triglycerides (mmol/L) 40 -0.47 <0.01 22% 
HDL (mmol/L) 40 0.52 <0.01 27% 
HDL:Total  40 -0.42 0.01 18% 
LDL(mmol/L) 40 0.17 0.29 3% 
VLDL (mmol/L) 40 -0.44 <0.01 19% 
Free Fatty Acids (mEq/L) 38 0.23 0.88 0% 
Plasma Phospholipid Levels (%) 
Saturated Fatty Acids 39 -0.66 <0.01 44% 
Transaturated Fatty Acids 39 0.34 0.03 12% 
Omega-3 Fatty Acids (total) 39 -0.08 0.62 1% 
Alpha linoleic acid 39 0.15 0.36 2% 
Eicosapentaenoic acid  39 -0.16 0.34 11% 
Docosahexaenoic acid 39 -0.04 0.80 0% 
Omega-6 Fatty Acids (total) 39 0.11 0.50 1% 
Omega-3:Omega-6 39 -0.09 0.58 1% 
Data expresses correlations between adiponectin and various anthropometric and biochemical 
parameters measured in 40 subjects. Due to insufficient plasma sample for some participants, 
one or more analytes may have been omitted. BMI, Body Mass Index; WC, waist 
circumference; WHtR, Waist:Height Ratio; WHpR, Waist:Hip Ratio; HOMA, Homeostasis 
Model of Assessment scores for Insulin Resistance (IR) and pancreatic beta cell function (); 
ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl 
transpeptidase; CRP, C-reactive protein. 
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Table 3. Spearman’s correlation coefficients and CVs for leptin levels 
Metabolic Parameters n 
Spearman’s correlation CV 
(r
2
 x 100) r P Value 
Anthropometric Parameters     
BMI (kg/m
2
) 40 0.44 <0.01 18% 
WC (m) 40 0.09 0.60 1% 
WHtR 40 0.34 0.03 12% 
WHpR 40 
-0.30 0.06 
9% 
Insulin Sensitivity 
Glucose (mmol/L) 40 0.19 0.23 4% 
Insulin (mU/L) 40 0.09 0.65 1% 
HbA1C (NgSP; %) 40 <0.01 0.99 0% 
HbA1C (IFCC; mmol/mol) 40 
<0.01 0.99 
0% 
Electrolyte and Liver Function 
ALT (U/L) 40 -0.12 0.48 1% 
AST (U/L) 40 0.06 0.71 0% 
GGT (U/L) 40 -0.06 0.70 0% 
Urea (mmol/L) 40 -0.22 0.17 5% 
Creatinine (mmol/L) 40 -0.51 <0.01 26% 
Urea:Creatinine  40 0.16 0.33 3% 
Urate (mmol/L) 40 -0.29 0.07 8% 
CRP (mh/L) 40 0.47 0.01 22% 
Blood Lipids 
Total Cholesterol (mmol/L) 40 -0.15 0.36 2% 
Triglycerides (mmol/L) 40 -0.21 0.20 4% 
HDL (mmol/L) 40 0.40 0.01 16% 
HDL:Total  40 -0.55 <0.01 30% 
LDL(mmol/L) 40 -0.21 0.18 4% 
VLDL (mmol/L) 40 -0.19 0.24 4% 
Free Fatty Acids (mEq/L) 38 0.11 0.51 1% 
Plasma Phospholipid Levels (%) 
Saturated Fatty Acids 39 -0.17 0.30 3% 
Transaturated Fatty Acids 39 -0.21 0.21 4% 
Omega-3 Fatty Acids (total) 39 -0.14 0.38 2% 
Alpha linoleic acid 39 0.33 0.04 11% 
Eicosapentaenoic acid  39 -0.09 0.60 36% 
Docosahexaenoic acid 39 -0.12 0.48 1% 
Omega-6 Fatty Acids (total) 39 0.15 0.37 2% 
Omega-3:Omega-6 39 -0.18 0.27 3% 
Data expresses correlations between leptin and various anthropometric and biochemical 
parameters measured in 40 subjects. Due to insufficient plasma sample for some participants, 
one or more analytes may have been omitted. BMI, Body Mass Index; WC, waist circumference; 
WHtR, Waist:Height Ratio; WHpR, Waist:Hip Ratio; HOMA, Homeostasis Model of Assessment 
scores for Insulin Resistance (IR) and pancreatic beta cell function (); ALT, alanine 
transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transpeptidase; CRP, C-
reactive protein. 
 
